{"id":"cee83a3c-1418-58c8-9474-a18e73bbe239","stable_key":"33bef151-bdc7-5892-aff6-0345ab149739:the-same-trial-reports-a-visuospatial-domain-difference","predicate":"increases","statement":"Exploratory analysis of the same trial found a between-group difference in visuospatial function change of 0.350 and a reduced risk of visuospatial decline.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"afa0770e-bc34-5d48-a19e-10cf8f5e156e","mechanism_event_label":"Exploratory analysis of the same trial found a between-group difference in visuospatial function change of 0.350 and a reduced risk of visuospatial decline.","subject":{"id":"e8eb9bb4-3c6f-5e96-a968-a6d1fece71e7","slug":"nattokinase-supplement","display_name":"Commercial nattokinase supplement, composition study-specific","entity_type_key":"chemical_species"},"object":{"id":"8a76c28e-6f77-5131-ad50-0d73db33bcd5","slug":"visuospatial-function-score","display_name":"Visuospatial function domain score","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"afa0770e-bc34-5d48-a19e-10cf8f5e156e","stable_key":"33bef151-bdc7-5892-aff6-0345ab149739:the-same-trial-reports-a-visuospatial-domain-difference-event","event_type":"observed_intervention","label":"Exploratory analysis of the same trial found a between-group difference in visuospatial function change of 0.350 and a reduced risk of visuospatial decline.","description":"Cognitive domain scores","status":"provisional","compartment":null,"participants":[{"entity":{"id":"e8eb9bb4-3c6f-5e96-a968-a6d1fece71e7","slug":"nattokinase-supplement","display_name":"Commercial nattokinase supplement, composition study-specific","entity_type_key":"chemical_species"},"role":"acting component","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"8a76c28e-6f77-5131-ad50-0d73db33bcd5","slug":"visuospatial-function-score","display_name":"Visuospatial function domain score","entity_type_key":"cellular_process"},"role":"component the finding is about","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"duration","value_text":"6 months","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Human (88 completers with asymptomatic stenosis)","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Nattokinase, 8,000 FU per day","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Exploratory and one of several domains, in a trial whose primary endpoint was null. Recorded as a domain-level finding, not as a cognitive benefit.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"organism","value_text":"Human (88 completers with asymptomatic stenosis)","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Exploratory analysis of the same trial found a between-group difference in visuospatial function change of 0.350 and a reduced risk of visuospatial decline.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Nattokinase supplementation for cognitive enhancement in asymptomatic intracranial/carotid stenosis: A randomized controlled trial. (2026) https://pubmed.ncbi.nlm.nih.gov/41325794/ DOI: 10.1016/j.jstrokecerebrovasdis.2025.108511","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"In vivo, oral","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"Cognitive domain scores","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"98c09715-1e64-56a0-8442-0de8e5942c7c","evidence_kind":"source_excerpt","locator":"Lines 1236-1236","start_line":1236,"end_line":1236,"excerpt":"Exploratory analysis of the same trial found a between-group difference in visuospatial function change of 0.350 and a reduced risk of visuospatial decline.","model_system":"Human (88 completers with asymptomatic stenosis)","directness":"reported_statement","verification_status":"source_derived_draft","notes":"","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"41cb127c-1c23-53aa-b7d0-5ec7f6fa3c99","stable_key":"import-33bef151-bdc7-5892-aff6-0345ab149739","title":"Nattokinase: what the purified enzyme cleaves, what survives being eaten, and the gap between the two (2026-09-23)","document_type":"imported_text","citation_label":"Original AI-assisted curation built from a supplied entity-first document of 105 entities and 129 claims. Every reference in that document was resolved against live PubMed with its abstract read and its DOI cross-checked on 2026-09-23, and the EFSA novel-food opinion was retrieved and read in full. That check corrected two PMIDs that pointed at unrelated papers, two DOIs, and two papers recorded as carrying no erratum that do carry one; it also reversed three findings the supplied document had stated backwards. Two papers carry a published correction, recorded as such and not as a retraction. Three sources are not indexed in PubMed and are cited by what they have. Laboratory lineages are recorded, so the four papers from one group, the three from another and the two readings of a single applicant dossier cannot be counted as separate lines of support. Study-specific doses, units, populations and limitations retained; activity units are never converted between systems. Not publisher full text.","file_path":"","sha256":"34fc46e0e849d06bfa13cb099a79b50679dd6fd0de8a5a0575326afdde3259c1","revision_id":"efd063e6-e982-5f6e-a4b8-6f2ffe4185ce","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}